Schering, Merck Cholesterol Prescriptions Slide
NEW YORK (Reuters) – U.S. prescriptions of Schering-Plow Corp’s cholesterol drugs fell 13 percent in February from a month earlier, following results of a controversial study, the drug maker said on Tuesday.
The drugs, Zetia and Vytorin, fell to 2.77 million total prescriptions in February from 3.19 million in January, Schering-Plow said in a filing. Schering-Plow sells the drugs with Merck & Co in a joint venture.
“Although the prescription data have shown some early signs of stabilization, there are limitations to this prescription data and it is too early to discern any trends,” Schering-Plow said.
It’s amazing that your news agency releases this story with the name Schering-Plough MISSPELLED throughout the article as Schering-Plow. THREE journalists let this error go undetected!
This was not human error – not even sloppy use of a spell-check. The spelling was correct for most of our services, but a renegade program changing British spellings to American spellings kicked in on one news feed. And yes, it was a bit ironic that it happened the week Arthur C. Clarke died: GBU Editor